Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Eteplirsen Review Timeline: CDER Director Was Involved Early And Often

Executive Summary

Review documents show eight center director briefings during the IND phase and seven after NDA submission of Sarepta's DMD drug.

Advertisement

Related Content

Exondys Approval: Measured Efficacy Outcomes Vs. Patient 'Anecdotes'
Scrip's Pharma Influencers Of 2016
Sarepta's Shadow: BioMarin Mulls Turning The Extraordinary Into A Template
Keeping Track: Ilaris Adds Three Rare Disease Claims; Sirukumab Submitted; Exondys 51's Surprising Approval
Eteplirsen Review Offers Lessons For FDA, Advocacy Groups, Industry
Sarepta's Eteplirsen Approved After Contentious Internal Debate
Sarepta's Eteplirsen Approved After Contentious Internal Debate

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119163

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel